Search Main Menu Main Content

Choose language
Change contrast :
Standards Reinforced

icone

HAS profile

Mission
Organisational Structure
Ethics, transparency and management of conflicts of interest

International relations and projects
Publications

Recherche

icone plus
My account

Email alert Subscription

Newsletter Subscription

My search

Refresh

Please fill in your email address to retrieve your email alerts subscriptions.

New subscription

Please fill in your email address to retrieve your newsletter subscriptions.

You do not have a saved search
No element in selection
Contact

1 result

Language : Français
Active substance : gabapentine
Active substance : citalopram

Topic

Diseases and conditions (1)
Plus ...
- Mental disorders and behavioural conditions (1)
- Plus ...
  - Anxiety and neurotic disorders (1)

Practice Guidelines and Other Guides (1)
Plus ...
- Chronic disease guide (1)

Date

Last five years (1)

Français (1)

Active substance

alcool (1)
alprazolam (1)
amitriptyline (1)
citalopram (1)
escitalopram (1)
gabapentine (1)
lithium (1)
propranolol (1)
venlafaxine (1)

Practice guidelines and other guides - 1 result

Long-term psychiatric conditions : Severe anxiety disorders

Chronic disease guide - Posted on 15/1/2018

Download guide

Add to my selection

Advancing quality in the fields of health and social care services

Follow us :

Eunetha.eu
Pasq.eu

All our publications by topic and type

Opinions on medicines
Opinions on medical devices
INAHTA briefs

Français
English

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

81B5mJM3wBtyqqTE